Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study

Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA).

As quoted in the press release:

Data from the PLAUDIT trial will be presented in a poster session today at the 60^th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, California.

In the ongoing PLAUDIT study, 12 CAD patients have been enrolled on APL-2 subcutaneous treatment, of which 5 patients have been treated for at least 56 days. Nine patients with wAIHA were enrolled, seven of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA). Five of these C3+ wAIHA patients have been on APL-2 for at least 56 days.

“CAD and wAIHA are now the third and fourth indications, along with paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA), with high unmet medical need where APL-2 has demonstrated proof of concept,” said Dr. Cedric Francois, MD, PhD, Apellis co-founder and CEO. “These additional data confirm that the unique way APL-2 targets both C3 as well as C5 via the C5 convertase supports its potential across multiple complement-mediated diseases.  We are pleased that APL-2 demonstrates a clinically meaningful benefit in these two challenging diseases that each lack an FDA-approved therapy.”

Click here to read the full press release.